Elly V Barry

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols
    Elly Barry
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:813-9. 2007
  2. ncbi Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin
    Elly V Barry
    Dana Farber Cancer Institute, Department of Pediatric Oncology, Boston, MA 02115, USA
    Blood 110:4476-9. 2007
  3. ncbi Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane
    Elly V Barry
    Departments of Pediatric Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1106-11. 2008
  4. ncbi Tolerability of pravastatin in pediatric hematopoietic stem cell transplant patients with bronchiolitis obliterans
    Christine N Duncan
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Pediatr Hematol Oncol 32:185-8. 2010
  5. ncbi Acute lymphoblastic leukemia in adolescents and young adults
    Elly V Barry
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Hematol Malig Rep 3:161-6. 2008

Detail Information

Publications5

  1. ncbi Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols
    Elly Barry
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:813-9. 2007
    ..We report the outcome of adolescents treated on Dana-Farber Cancer Institute (DFCI; Boston, MA) ALL Consortium Protocols conducted between 1991 and 2000...
  2. ncbi Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin
    Elly V Barry
    Dana Farber Cancer Institute, Department of Pediatric Oncology, Boston, MA 02115, USA
    Blood 110:4476-9. 2007
    ..We conclude that midostaurin is a potent inhibitor of a spectrum of FLT3 activation loop mutations, and that acute myeloid leukemia patients with such mutations are potential candidates for clinical trials involving midostaurin...
  3. ncbi Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane
    Elly V Barry
    Departments of Pediatric Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1106-11. 2008
    ..We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01...
  4. ncbi Tolerability of pravastatin in pediatric hematopoietic stem cell transplant patients with bronchiolitis obliterans
    Christine N Duncan
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Pediatr Hematol Oncol 32:185-8. 2010
    ..No other patient had a clinically relevant change in white blood cell count, platelet count, or hemoglobin. Pravachol was well tolerated and safe in this group of patients, and merits further study in this patient population...
  5. ncbi Acute lymphoblastic leukemia in adolescents and young adults
    Elly V Barry
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Hematol Malig Rep 3:161-6. 2008
    ..Pilot prospective studies are under way to test the feasibility of administering pediatric ALL regimens to AYAs with ALL, with promising preliminary results...